Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (925)

« Back to Publications

Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.

Vassy JL. et al, (2026), Nat Cancer

ctive Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial.

Sushentsev N. et al, (2025), JAMA Oncol, 11, 1512 - 1517

Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.

Martin RM. et al, (2024), JAMA, 331, 1460 - 1470

ssociation between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis.

Yarmolinsky J. et al, (2024), EBioMedicine, 100

Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.

Wang A. et al, (2023), Nat Genet, 55, 2065 - 2074

Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.

Yarmolinsky J. et al, (2023), Diabetologia, 66, 1481 - 1500

Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry.

Darst BF. et al, (2023), Am J Hum Genet, 110, 1200 - 1206

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Hamdy FC. et al, (2023), N Engl J Med, 388, 1547 - 1558

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.

Keeney E. et al, (2022), Pharmacoeconomics, 40, 1207 - 1220

The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.

Buhigas C. et al, (2022), Mol Cancer, 21

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).

Lane JA. et al, (2022), BJU Int, 130, 370 - 380

comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections.

Lloyd P. et al, (2022), World J Urol, 40, 119 - 126

Correction to 'Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation'.

Gaughan L. et al, (2021), Nucleic Acids Res, 49, 10203 - 10206

Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.

Karlsson Q. et al, (2021), Eur Urol Oncol, 4, 570 - 579

dditional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.

Karunamuni RA. et al, (2021), Prostate Cancer Prostatic Dis, 24, 532 - 541

Load More

1
2
3
4
5
6
7
...
»